Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Avantor (NYSE: AVTR) reported Q1 2026 results for the quarter ended March 31, 2026. Net sales were $1,581.4 million, flat year-over-year; organic sales declined 4.1%. Net income was $43.3 million (GAAP); adjusted net income was $114.0 million. Adjusted EBITDA was $219.4 million (13.9% margin). Diluted GAAP EPS was $0.06; adjusted EPS was $0.17. Operating cash flow was $58.7 million and free cash flow was $25.2 million. GAAP net leverage was (6.5x); adjusted net leverage was 3.3x. Segment highlights: VWR sales $1,150.0 million (organic -4.8%; adj. op income $105.4 million, 9.2% margin); Bioscience & Medtech sales $431.4 million (organic -2.0%; adj. op income $102.7 million, 23.8% margin). Company reaffirmed FY 2026 guidance and will host a conference call April 29, 2026 at 8:00 a.m. ET.
Avantor (NYSE: AVTR) appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026. He will lead BMP growth, improve operational performance, and head the Revival Management Office to drive enterprise transformation. Benoit Gourdier will remain through end of 2026 to transition the role.
Avantor (NYSE: AVTR) unified its Masterflex fluid handling portfolio to include standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, systems, PROFINET connectivity, and new storage containers for R&D through high-volume bioprocess manufacturing.
Avantor will demonstrate integrated systems and a technical presentation at INTERPHEX 2026 in New York, April 21–23.
Avantor (NYSE: AVTR) expanded its St. Louis site on April 13, 2026, adding GMP-aligned microbial testing and ICH-compliant stability testing and storage to strengthen U.S. biomanufacturing support.
The upgrade localizes testing previously done externally, supports 2,000+ microbial samples annually, aims to speed turnaround, improve data visibility, and reduce supply chain complexity for regulated biopharma applications.
Avantor (NYSE: AVTR) will report first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026, and will host a conference call the same day at 8:00 a.m. Eastern Daylight Time. A live audio webcast will be available via the company’s Investor Events & Presentations page, with a replay accessible for 30 days.
Avantor (NYSE: AVTR) announced that CFO R. Brent Jones will leave the company on or before June 24, 2026, and that Senior VP and Chief Accounting Officer Steve Eck will serve as interim CFO upon Jones' departure. The company has started a search for a permanent CFO.
Avantor also reaffirmed its fiscal 2026 guidance provided on February 11, 2026, signaling continuity in financial expectations during the leadership transition.
Avantor (NYSE: AVTR) reported fourth-quarter and full-year 2025 results and outlined a “Revival” turnaround program. Q4 net sales were $1.66B (down 1%; organic -4%), adjusted EBITDA was $252M, and adjusted EPS was $0.22. Full-year 2025 sales were $6.55B (down 3%; organic -3%), adjusted EBITDA $1,069M, GAAP net loss $530M, and adjusted EPS $0.90. Management cited brand relaunch, supply chain and e-commerce upgrades and expects 2026 to be a transition year with investments to restore top-line growth.
Invesco Mortgage Capital (NYSE: IVR) declared a cash dividend of $0.12 per common share for January 2026, payable February 13, 2026, to holders of record on January 26, 2026 (ex-dividend January 26, 2026).
As of January 12, 2026 management estimates book value per common share at $8.94 to $9.30, a debt-to-equity ratio of 6.5x, and an economic debt-to-equity ratio of 6.9x. Repurchase agreements total $5.6 billion and TBAs at implied cost are $385.4 million. These figures are preliminary, unaudited estimates and may change.
Avantor (NYSE: AVTR) will release its fourth quarter and full year 2025 financial results before market open on Wednesday, February 11, 2026. The company will host a conference call the same day at 8:00 a.m. Eastern Standard Time to discuss the results. Investors can listen via a live audio webcast on the Investor Events & Presentations page at ir.avantorsciences.com. A replay of the webcast will be available for 30 days following the live session.
Avantor (NYSE: AVTR) announced that Emmanuel Ligner, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at approximately 8:15 a.m. Pacific Standard Time. A live audio webcast will be available through the company’s Investor Events & Presentations page at ir.avantorsciences.com, and a replay will be accessible for 30 days.